Viatris

Services: Global healthcare company formed in November 2020 via Mylan-Upjohn combination; portfolio spans branded (Xulane, Yupelri, Effient, Dilantin, Cordarone, Sarafem, Dymista), generics (~1,400 molecules across all therapeutic areas), biosimilars, complex generics; therapeutic focus: cardiology, infectious disease, immunology, oncology, ophthalmology, dermatology, respiratory, CNS; significant emerging markets presence through legacy Mylan platforms; now executing Phase II of strategic plan with portfolio optimization